Emergent Biosolutions Stock Performance
| EBS Stock | USD 7.17 0.04 0.56% |
On a scale of 0 to 100, Emergent Biosolutions holds a performance score of 7. The firm shows a Beta (market volatility) of 2.93, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Emergent Biosolutions will likely underperform. Please check Emergent Biosolutions' jensen alpha, skewness, relative strength index, as well as the relationship between the value at risk and day median price , to make a quick decision on whether Emergent Biosolutions' price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Emergent Biosolutions are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating fundamental drivers, Emergent Biosolutions unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (4.02) | Five Day Return (2.18) | Year To Date Return (30.18) | Ten Year Return (78.13) | All Time Return (38.72) |
1 | Acquisition by Louis Sullivan of 15824 shares of Emergent Biosolutions at 5.45 subject to Rule 16b-3 | 04/30/2025 |
2 | Kevin Vilkin Joins Milken Young Leaders Circle | 05/02/2025 |
3 | Acquisition by Joseph Papa of 60000 shares of Emergent Biosolutions at 5.83 subject to Rule 16b-3 | 05/13/2025 |
4 | CoreCap Advisors LLC Cuts Holdings in Emergent BioSolutions Inc. | 05/14/2025 |
5 | Acquisition by Richard Lindahl of 146888 shares of Emergent Biosolutions subject to Rule 16b-3 | 06/04/2025 |
6 | Emergent BioSolutions Supports Victorias Voice Foundations National Naloxone Awareness Day ... | 06/05/2025 |
7 | Disposition of 2733 shares by Richard Lindahl of Emergent Biosolutions at 6.63 subject to Rule 16b-3 | 06/06/2025 |
8 | Emergent BioSolutions Secures 62.4 Million Contract Modification for BAT Botulism Antitoxin Heptavalent to Bolster U.S. Biodefense Supply | 06/23/2025 |
9 | Uber Buy Point, Carnival Stock Breakout Highlight Emergent Strength In This Industry Group | 06/26/2025 |
10 | Emergent BioSolutions Expands NARCANDirect to Offer KLOXXADO Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate | 07/02/2025 |
11 | Emergent Biosolutions bags 51.9M contract modification award for smallpox preparedness | 07/08/2025 |
12 | Disposition of 4263 shares by William Hartzel of Emergent Biosolutions at 7.36 subject to Rule 16b-3 | 07/11/2025 |
13 | Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 EBS ... | 07/15/2025 |
14 | BlackRock, Inc. Expands Stake in Emergent BioSolutions Inc | 07/24/2025 |
| Begin Period Cash Flow | 111.7 M | |
| Total Cashflows From Investing Activities | 125.2 M |
Emergent Biosolutions Relative Risk vs. Return Landscape
If you would invest 545.00 in Emergent Biosolutions on April 27, 2025 and sell it today you would earn a total of 167.50 from holding Emergent Biosolutions or generate 30.73% return on investment over 90 days. Emergent Biosolutions is generating 0.6164% of daily returns assuming volatility of 6.4227% on return distribution over 90 days investment horizon. In other words, 57% of stocks are less volatile than Emergent, and above 88% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Emergent Biosolutions Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Emergent Biosolutions' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Emergent Biosolutions, and traders can use it to determine the average amount a Emergent Biosolutions' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.096
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EBS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.42 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.62 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Emergent Biosolutions is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Emergent Biosolutions by adding it to a well-diversified portfolio.
Emergent Biosolutions Fundamentals Growth
Emergent Stock prices reflect investors' perceptions of the future prospects and financial health of Emergent Biosolutions, and Emergent Biosolutions fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Emergent Stock performance.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0161 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 932.37 M | ||||
| Shares Outstanding | 54.28 M | ||||
| Price To Earning | 1.67 X | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 0.42 X | ||||
| Revenue | 1.01 B | ||||
| Gross Profit | 354 M | ||||
| EBITDA | 36.9 M | ||||
| Net Income | (190.6 M) | ||||
| Cash And Equivalents | 99.5 M | ||||
| Cash Per Share | 7.28 X | ||||
| Total Debt | 663.7 M | ||||
| Debt To Equity | 0.56 % | ||||
| Current Ratio | 3.92 X | ||||
| Book Value Per Share | 10.14 X | ||||
| Cash Flow From Operations | 58.7 M | ||||
| Earnings Per Share | (2.58) X | ||||
| Market Capitalization | 405.46 M | ||||
| Total Asset | 1.39 B | ||||
| Retained Earnings | (212.4 M) | ||||
| Working Capital | 436.3 M | ||||
| Current Asset | 537.41 M | ||||
| Current Liabilities | 99.61 M | ||||
About Emergent Biosolutions Performance
Assessing Emergent Biosolutions' fundamental ratios provides investors with valuable insights into Emergent Biosolutions' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Emergent Biosolutions is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 113.8 B | 119.5 B | |
| Return On Tangible Assets | (0.21) | (0.20) | |
| Return On Capital Employed | (0.09) | (0.08) | |
| Return On Assets | (0.14) | (0.13) | |
| Return On Equity | (0.39) | (0.38) |
Things to note about Emergent Biosolutions performance evaluation
Checking the ongoing alerts about Emergent Biosolutions for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Emergent Biosolutions help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Emergent Biosolutions is way too risky over 90 days horizon | |
| Emergent Biosolutions appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 1.01 B. Reported Net Loss for the year was (190.6 M) with profit before taxes, overhead, and interest of 354 M. | |
| About 67.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: BlackRock, Inc. Expands Stake in Emergent BioSolutions Inc |
- Analyzing Emergent Biosolutions' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Emergent Biosolutions' stock is overvalued or undervalued compared to its peers.
- Examining Emergent Biosolutions' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Emergent Biosolutions' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Emergent Biosolutions' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Emergent Biosolutions' stock. These opinions can provide insight into Emergent Biosolutions' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.